L & S Advisors Inc lessened its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 9.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 29,685 shares of the biopharmaceutical company’s stock after selling 3,196 shares during the quarter. L & S Advisors Inc’s holdings in Alexion Pharmaceuticals were worth $3,888,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ALXN. Artisan Partners Limited Partnership increased its stake in Alexion Pharmaceuticals by 220.9% during the 1st quarter. Artisan Partners Limited Partnership now owns 4,248,248 shares of the biopharmaceutical company’s stock worth $574,278,000 after buying an additional 2,924,550 shares during the period. FMR LLC boosted its holdings in shares of Alexion Pharmaceuticals by 10.4% in the 1st quarter. FMR LLC now owns 29,144,320 shares of the biopharmaceutical company’s stock valued at $3,939,729,000 after buying an additional 2,746,055 shares during the period. Jennison Associates LLC boosted its holdings in shares of Alexion Pharmaceuticals by 17.3% in the 1st quarter. Jennison Associates LLC now owns 10,241,457 shares of the biopharmaceutical company’s stock valued at $1,384,440,000 after buying an additional 1,512,545 shares during the period. FIL Ltd boosted its holdings in shares of Alexion Pharmaceuticals by 629.3% in the 1st quarter. FIL Ltd now owns 1,208,567 shares of the biopharmaceutical company’s stock valued at $163,373,000 after buying an additional 1,042,846 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in shares of Alexion Pharmaceuticals by 104.9% in the 2nd quarter. Renaissance Technologies LLC now owns 1,642,542 shares of the biopharmaceutical company’s stock valued at $215,140,000 after buying an additional 840,742 shares during the period. Institutional investors own 93.23% of the company’s stock.

In other news, insider Aradhana Sarin sold 578 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $132.00, for a total transaction of $76,296.00. Following the transaction, the insider now directly owns 30,201 shares in the company, valued at approximately $3,986,532. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Indrani Lall Franchini sold 4,500 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $132.78, for a total value of $597,510.00. Following the completion of the transaction, the executive vice president now owns 29,627 shares in the company, valued at $3,933,873.06. The disclosure for this sale can be found here. Company insiders own 4.08% of the company’s stock.

Several research analysts have recently commented on ALXN shares. Robert W. Baird set a $165.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 30th. Leerink Swann set a $157.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, September 3rd. Raymond James set a $168.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 30th. Citigroup set a $150.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 30th. Finally, BMO Capital Markets started coverage on shares of Alexion Pharmaceuticals in a report on Thursday. They issued an “outperform” rating and a $149.00 price target for the company. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $160.44.

ALXN stock traded down $0.04 during midday trading on Friday, reaching $108.22. 91,679 shares of the company traded hands, compared to its average volume of 3,154,441. Alexion Pharmaceuticals, Inc. has a 52-week low of $92.56 and a 52-week high of $141.86. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.56 and a current ratio of 4.04. The business has a 50 day moving average of $110.12 and a 200-day moving average of $124.61. The firm has a market capitalization of $24.58 billion, a price-to-earnings ratio of 15.26, a P/E/G ratio of 1.04 and a beta of 1.67.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.51. The business had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.18 billion. Alexion Pharmaceuticals had a return on equity of 20.23% and a net margin of 29.64%. The company’s revenue was up 15.1% on a year-over-year basis. During the same quarter last year, the business posted $2.07 EPS. Research analysts anticipate that Alexion Pharmaceuticals, Inc. will post 9.03 earnings per share for the current year.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

See Also: Why are trading ranges significant?

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.